Hyaluronic acid for ophthalmology applications

The use of Novozymes Biopharma Novozymes Bacillus-derived hyaluronic acid (HA) in ophthalmic treatments confers moisturisation properties and offers the ability to extend drug retention time.

The product provides optimal viscosity profiles for convenient application and increased patient comfort and compliance while superior heat stability permits autoclaving without loss of product viscosity.The ingredient also has a dissolving time of up to five times faster which can result in savings on manufacturing costs and production time.

A new poster entitled ‘New recombinant hyaluronic acid for eye care and ophthalmic drug delivery’, evaluates the corneal tolerance of Novozymes’ HA with the use of confocal laser screening ophthalmoscopy.

The results indicate that repeated applications of formulations containing HA onto the cornea do not induce corneal lesions. In addition, the study demonstrates that Bacillus-derived HA offers superior stability during autoclaving when compared to a competitor product. The poster concludes that the high purity and biocompatibility of Novozymes’ HA, combined with its superior stability during autoclaving, makes it an ingredient of choice for formulations intended for eye care and ophthalmic drug delivery.

For more information, visit www.biopharma.novozymes.com

Recent Issues